Publicaciones en colaboración con investigadores/as de Hospital Universitario de Salamanca (17)

2009

  1. Association between cerebral metabolic and structural abnormalities and cognitive performance in schizophrenia

    Psychiatry Research - Neuroimaging, Vol. 173, Núm. 2, pp. 88-93

2008

  1. Differential clinical, structural and P300 parameters in schizophrenia patients resistant to conventional neuroleptics

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 32, Núm. 1, pp. 257-266

  2. Gray matter deficits in bipolar disorder are associated with genetic variability at interleukin-1 beta gene (2q13)

    Genes, Brain and Behavior, Vol. 7, Núm. 7, pp. 796-801

2007

  1. Changes in cortical volume with olanzapine in chronic schizophrenia

    Pharmacopsychiatry, Vol. 40, Núm. 4, pp. 135-139

  2. Dorsolateral prefrontal N-acetyl-aspartate concentration in male patients with chronic schizophrenia and with chronic bipolar disorder

    European Psychiatry, Vol. 22, Núm. 8, pp. 505-512

  3. Effect of interleukin-1β gene functional polymorphism on dorsolateral prefrontal cortex activity in schizophrenic patients

    American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics, Vol. 144, Núm. 8, pp. 1090-1093

  4. Marked hypofrontality in clozapine-responsive patients

    Pharmacopsychiatry, Vol. 40, Núm. 4, pp. 157-162

  5. No association between dorsolateral prefrontal gray matter deficit and N-acetyl aspartate ratios in schizophrenia

    Neuropsychobiology, Vol. 54, Núm. 3, pp. 171-178

2006

  1. Dorsolateral prefrontal and superior temporal volume deficits in first-episode psychoses that evolve into schizophrenia

    European Archives of Psychiatry and Clinical Neuroscience, Vol. 256, Núm. 2, pp. 106-111

2005

  1. Association between excessive frontal cerebrospinal fluid and illness duration in males but not in females with schizophrenia

    European Psychiatry, Vol. 20, Núm. 4, pp. 332-338

  2. Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement

    Psychopharmacology, Vol. 178, Núm. 1, pp. 17-26

  3. Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia

    Schizophrenia Research, Vol. 80, Núm. 1, pp. 61-71

  4. N-acetyl-aspartate levels in the dorsolateral prefrontal cortex in the early years of schizophrenia are inversely related to disease duration

    Schizophrenia Research, Vol. 73, Núm. 2-3, pp. 209-219

  5. Olanzapine-induced cerebral metabolic changes related to symptom improvement in schizophrenia

    International Clinical Psychopharmacology, Vol. 20, Núm. 1, pp. 13-18

  6. Ventricular enlargement in schizophrenia is associated with a genetic polymorphism at the interleukin-1 receptor antagonist gene

    NeuroImage, Vol. 27, Núm. 4, pp. 1002-1006

2004

  1. Direct association between orbitofrontal atrophy and the response of psychotic symptoms to olanzapine in schizophrenia

    International Clinical Psychopharmacology, Vol. 19, Núm. 4, pp. 221-228

  2. Lower prefrontal gray matter volume in schizophrenia in chronic but not in first episode schizophrenia patients

    Psychiatry Research - Neuroimaging, Vol. 131, Núm. 1, pp. 45-56